Renal Denervation as a Complementary Treatment Option for Uncontrolled Arterial Hypertension: A Situation Assessment

J Clin Med. 2023 Aug 29;12(17):5634. doi: 10.3390/jcm12175634.

Abstract

Uncontrolled arterial hypertension is a major global health issue. Catheter-based renal denervation has shown to lower blood pressure in sham-controlled trials and represents a device-based, complementary treatment option for hypertension. In this situation assessment, the authors, who are practicing experts in hypertension, nephrology, general practice and cardiology in the Republic of Ireland, discuss the current evidence base for the BP-lowering efficacy and safety of catheter-based renal denervation with different modalities. Although important questions remain regarding the identification of responders, and long-term efficacy and safety of the intervention, renal denervation has the potential to provide much-needed help to address hypertension and its adverse consequences. The therapeutic approach needs to be multidisciplinary and personalised to take into account the perspective of patients and healthcare professionals in a shared decision-making process.

Keywords: arterial hypertension; renal denervation; resistant hypertension; uncontrolled hypertension.

Publication types

  • Review

Grants and funding

A general research grant to develop the consensus document for renal artery denervation for Irish hospitals was provided by Medtronic Ireland Ltd. The national advisory board of doctors (listed as co-authors) and not the company (Medtronic Ireland Ltd) had scientific oversight over the content and integrity of this publication. Max Wagener has received a research and clinical fellowship grant from the Gottfried & Julia Bangerter-Rhyner Foundation, Switzerland. Faisal Sharif’s research group is funded by research grants from the Science Foundation Ireland.